Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics

Current Diabetes Reports

Volumn 15, Issue 8, 2015, Pages

  Pramyothin, Pornpoj ^a   Khaodhiar, Lalita ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Children and adolescents; Diabetes; Obesity; Psychosis; Serious mental illness

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; ILOPERIDONE; INSULIN; LURASIDONE; METFORMIN; MOLINDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; NEUROLEPTIC AGENT;

ABDOMINAL CRAMP; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; AUTISM; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FOOD INTAKE; FTO GENE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HEALTH DISPARITY; HEALTH INSURANCE; HTR2C GENE; HUMAN; HYPERTENSION; HYPOTHALAMUS; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LEP GENE; LIFESTYLE MODIFICATION; MC4R GENE; META ANALYSIS (TOPIC); MTHFR GENE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRACTICE GUIDELINE; PREHYPERTENSION; PREVALENCE; PSYCHIATRIST; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN; ADOLESCENT; CHEMICALLY INDUCED; CHILD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIFESTYLE; METABOLISM;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; LIFE STYLE; OBESITY; WEIGHT GAIN;

EID: 84935853947     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0623-4     Document Type: Review

References (67)

1. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry: J Mental Sci. 2010;196(2):116–21.
2. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64–6.
3. Casagrande SS, Anderson CA, Dalcin A, Appel LJ, Jerome GJ, Dickerson FB, et al. Dietary intake of adults with serious mental illness. Psychiatric Rehabil J. 2011;35(2):137–40.
4. Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009;31(6):555–63.
5. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014;311(2):172–82.
6. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861–7.
7. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123(2–3):234–43.
8. Kilbourne AM, McCarthy JF, Post EP, Welsh D, Pincus HA, Bauer MS, et al. Access to and satisfaction with care comparing patients with and without serious mental illness. Int J Psychiatry Med. 2006;36(4):383–99.
9. Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol. 2010;24(4 Suppl):61–8.
10. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–56.
11. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacol. 2008;23 Suppl 1:15–26.
12. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460–6.
13. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067–75. Recent estimates of T2D disease burden in youths taking antipsychotics in the US.
14. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135–41.
15. Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case–control study. J Am Acad Child Adolesc Psychiatry. 2014;53(9):971–9 e6. Recent estimates of T2D disease burden in youths taking antipsychotics in Denmark.
16. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008;42(9):1316–22.
17. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63. Describes metabolic profile of a young patient cohort early on in the course of psychiatric disease.
18. Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15(3):202–14.
19. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18(8):1646–51.
20. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends endocrinol Metabolism: TEM. 2014;25(11):593–600. Excellent review of hypothesis and recent findings on antipsychotics and diabetes.
21. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity Metabolism. 2009;11(7):665–79.
22. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341–50.
23. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–26. Comprehensive review on the topic.
24. Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79–89. Comprehensive review on the topic.
25. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry: J Assoc Eur Psychiatrists. 2011;26(3):144–58.
26. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4), e94112. Summarizes data on weight gain associated with various antipsychotics.
27. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–33.
28. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–73.
29. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–59.
30. Kao AC, Muller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics. 2013;14(16):2067–83. Comprehensive review on the topic.
31. Shams TA, Muller DJ. Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Current Psychiatry Reports. 2014;16(10):473. Comprehensive review on the topic.
32. Ngai YF, Sabatini P, Nguyen D, Davidson J, Chanoine JP, Devlin AM, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014;34(3):359–64. Demonstrates effects of quetiapine on beta cell function in youths.
33. Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Shiffeldrim D, et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013;143(2–3):358–62.
34. Starrenburg FC, Bogers JP. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(3):164–70.
35. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232–40. Demonstrates weight-independent effects of antipsychotics on insulin resistance.
36. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.
37. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(6):412–24.
38. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry: J Mental Sci. 2011;199(2):99–105.
39. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, Cg g. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Canadian Acad Child Adolescent Psychiatry. 2011;20(3):218–33.
40. Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73(4):460–6. Describes prevalence and clinical characteristics of prediabetes in this patient group.
41. American Diabetes Association. Standards of Medical Care in Diabetes. 11. Children and adolescents. Diabetes Care. 2015;38(Supplement 1):S70–S6.
42. Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82.
43. National Institute for Health and Clinical Excellence. Diabetes in children and young people: diagnosis and management of type 1 and type 2 diabetes in children and young people. London, UK. 2015. http://www.nice.org.uk/guidance/indevelopment/gid-cgwaver118.
44. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
45. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.
46. Werneke U, Taylor D, Sanders TA. Behavioral interventions for antipsychotic induced appetite changes. Current Psychiatry Reports. 2013;15(3):347. Discusses aspects of behavioral intervention in this patient group.
47. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):e424–40.
48. Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71–81. Evaluates efficacy of lifestyle intervention in patients with SMI who receive antipsychotics.
49. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–602. Evaluates efficacy of lifestyle intervention in patients with SMI, most of whom receive antipsychotics.
50. Arnoldy R, Curtis J, Samaras K. The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabet Med. 2014;31(3):e16–9. A case report demonstrating dramatic effects of antipsychotic switching on glucose metabolism.
51. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12, CD006629.
52. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry: J Assoc Eur Psychiatrists. 2010;25 Suppl 2:S12–21.
53. Curtis J, Newall H, Myles N, Shiers D, Samaras K. Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatr Scand. 2012;126(4):302–3. Perspectives on the topic.
54. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol. 2012;27(2):69–75. Review of metformin use in adults and pediatric patients with psychiatric illnesses.
55. Hasnain M, Fredrickson SK, Vieweg WV. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J Psychopharmacol. 2011;25(6):715–21.
56. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–403. Review of use of metformin and other pharmacological agents in adults and pediatric patients with schizophrenia.
57. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159(4):655–7.
58. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–9.
59. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130–4.
60. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–93.
61. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925–7.
62. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry: J Mental Sci. 2009;194(6):491–9.
63. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–47. Demonstrates disparities in health care among patients with SMI.
64. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631–8.
65. Shiers D, Curtis J. Cardiometabolic health in young people with psychosis. Lancet Psychiatry. 2014;1(7):492–4. Describes the history and goals of the HeAL initiative.
66. International physical health in youth stream (iphYs). Healthy Active Lives (HeAL) statement., Sydney, Australia. 2014. http://www.iphys.org.au/. Further information on the HeAL initiative.
67. Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry. 2012;6(3):347–53. Discusses framework for early cardiometabolic intervention in youths with SMI who receive antipsychotics.